28 results about "Topical uses" patented technology

The invention relates to a product for topical use in the treatment of skin affected by dysbiosis. The product has a pH ranging from 5.5 to 6.5 and essentially comprises water, glycerin and at least one crosslinked polyacrylate. This product can be used as a prerequisite for the transplantation of biological material favorable to the development of a healthy cutaneous bacterial flora.

A biocompatible adhesive suitable for both internal and topical use. The adhesive is a tissue-adhesive hydrogel formed from an oxidized carboxymethylcellulose (oCMC) with aldehyde functional groups and a methacrylated methylcellulose (mMC).

The present invention provides a new silicone gel composition suitable for preparing an anti-herpes viruses product of natural origin. The new composition is capable of permeating at the target epidermis side of the skin. The new composition is capable of retaining in the target epidermis side of the skin for a certain period. The present invention also relates to the topical use of the silicone gel composition for the treatment of viruses of the herpes family at a posology regime.

The object of the present invention is Udonitrectag (or Negermin or MTS. IUPAC name (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid lysine salt) and pharmaceutical formulation thereof for topical use for use in the treatment of dermatological diseases. i.e. of the skin and mucous membranes.

The present invention relates to a composition and method for solubilizing eggshell membrane at convenient rates. The present invention also relates to organoleptically acceptable products obtained therein, and to their oral or topical application to improve a disease or condition in a subject.

A method for reducing the amount of sebum produced by human skin and / or by the scalp, for preventing, reducing, slowing down, stopping, and / or attenuating the appearance of unsightly, uncomfortable, and / or unpleasant manifestations of the skin and / or scalp in humans due to the secretion of sebum includes topically applying an extract of the alga Halopteris scoparia. Cosmetic or pharmaceutical compositions, in particular dermatological compositions, for topical use, containing an extract of the alga Halopteris scoparia, are also described.

Pharmaceutical compositions for topical use containing diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing treatments requiring the administration of high and accurate dosages to be carried out.

To provide a topical skin composition that has moderate viscosity while exhibiting excellent stability over time. [Solution] A composition for topical use on the skin, comprising the following components (A) to (F): (A) a polyglycerin fatty acid ester in which R in the fatty acid-derived group R-COO- is an alkyl group having 13 to 23 carbon atoms or an alkenyl group having 13 to 23 carbon atoms; (B) a polyhydric alcohol of trivalent or higher; (C) a polyhydric alcohol of divalent value; (D) an oily component that is liquid at 25°C; (E) a compound represented by formula (I), its salts and mixtures thereof; and (F) a nonionic surfactant other than component (A) and component (E) with an HLB of 4.5 to 12.0, and substantially free of water.

The invention relates to a novel topical pharmaceutical composition comprising ceftizoxime, a third-generation cephalosporin antibiotic, complexed with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) to enhance solubility and stability in aqueous environments. The sterile, sprayable formulation is intended for direct topical use or dilution for the treatment and prevention of bacterial skin and wound infections. To overcome ceftizoxime's aqueous instability, the invention employs inclusion complexation with 2–10% w / v SBE-β-CD, prepared by shaking at 30°C for 72 hours followed by sterile filtration. Differential Scanning Calorimetry (DSC) confirms molecular encapsulation through suppression of the ceftizoxime melting peak, indicating loss of crystallinity. Antibacterial efficacy is demonstrated against Staphylococcus aureus and Escherichia coli using zone of inhibition assays. UV–Vis spectrophotometry at 258 nm confirms high linearity (R² = 0.998) for quantitative analysis. The formulation offers a stable, scalable, and patient-friendly alternative for localized antibiotic therapy and surgical prophylaxis with reduced systemic exposure.

The problem that this invention aims to solve is the development of a composition intended to protect the skin from ultraviolet rays and that does not have the drawbacks of the prior art. [Solution] The present invention relates to a topical composition that generates a photonic barrier from ultraviolet to visible light, comprising metal-doped crystalline bismuth oxide colloid Bi2O3.

The present invention discloses the preparation and therapeutic properties of a gel consisting of the active ingredients diclofenac sodium and lysine clonixinate, which are combined for the first time for the topical treatment of pain in musculoskeletal inflammatory processes.

The present invention relates to compositions comprising an IRAK4 inhibitor useful for treating dermatological disorders or conditions characterized by inflammation. The present invention also relates to methods for treating dermatological disorders or conditions.

The formulation describe the preparation of an analgesic balm which comprises camphor, menthol, thymol, essential oils; e.g., wintergreen oil, eucalyptus oil, turpentine oil & cinnamomun oil; and hard wax in petroleum jelly base. This preparation is excellent in the precutanous absorption of menthol, thymol and provides good result upon use. It is prepared for topical use and effective for stiff joint pain, sciatica, headache and deep seated muscular pain. Its result is much better than othef marketed available drugs for same purpose.

This invention relates to topical pharmaceutical preparations containing nanosystems based on Lippia sidoides Cham. (rosemary-pepper) essential oil or thymol, indicated for the treatment of inflammatory diseases. The present invention relates to topical pharmaceutical preparations containing nanosystems such as polymeric nanoparticles or nanoemulsions, based on Lippia sidoides Cham. essential oil, or the isolated compound thymol, carried in pharmaceutical preparations in liquid or semi-solid forms, indicated for the treatment of inflammatory diseases. This invention also contemplates the standardization of the essential oil used as an active ingredient in these preparations, as well as the method of preparing the nanosystems consisting of polymeric nanoparticles or nanoemulsions, as well as their compositions and their potential in the treatment of inflammatory diseases.

This patent relates to a novel phytotherapeutic compound for topical use, specially formulated for the treatment of burns. The innovation lies in the use of a formulation that combines passion fruit leaves (Passiflora sp.) and refined pork fat, providing a natural and effective approach to the management of skin burns. Passion fruit leaves are processed by infusion to extract flavonoids, known for their anti-inflammatory and antioxidant properties, which reduce inflammation and oxidative stress in damaged tissue, facilitating healing. Refined pork fat, chosen for its rich composition of essential fatty acids and its emollient properties, serves as the base for the ointment, helping to absorb the active ingredients and to form a protective barrier that minimises transepidermal water loss and protects against infections. The method of obtaining the compound involves frying the fat to extract lipids, followed by filtration for purification. Subsequently, passion fruit leaf extracts are combined with the purified fat and the mixture is evaporated until it reaches the appropriate consistency for an ointment. This composition not only accelerates the healing of burns, but also significantly alleviates the pain and discomfort associated with such injuries. The compound offers an effective and safe alternative to conventional burn treatments, standing out due to its simplicity, efficacy, and use of natural ingredients, making it particularly valuable in regions with limited access to medical resources.

The present disclosure provides a solution composition comprising about 0.5% w / v to about 30% w / v of atomoxetine and about 0.1% w / v to about 20% w / v of oxybutynin, a penetration enhancer, at least 40% w / v of an aliphatic solvent, and a film forming excipient, wherein the composition forms a washable and / or a peelable film when sprayed on a skin surface, and wherein the atomoxetine and oxybutynin do not crystallize before dermal absorption when the composition is applied to the skin surface. The disclosure also provides a method of treating obstructive sleep apnea in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.

It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.

The present disclosure provides a solution composition comprising about 0.5% w / v to about 30% w / v of atomoxetine and about 0.1% w / v to about 20% w / v of oxybutynin, a penetration enhancer, at least 40% w / v of an aliphatic solvent, and a film forming excipient, wherein the composition forms a washable and / or a peelable film when sprayed on a skin surface, and wherein the atomoxetine and oxybutynin do not crystallize before dermal absorption when the composition is applied to the skin surface. The disclosure also provides a method of treating obstructive sleep apnea in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.

The present invention relates to a phytological composition for topical use in the treatment of non-skin inflammatory diseases and associated chronic pain. The phytological composition consists of a polysaccharide of Tremella fuciformis, an extract of leaves of Vitis vinifera, an extract of leaves of Astragalus membranaceus, an extract of Medicago sativa, an extract of Fucus vesiculosus, a powder of Spirulia platensis, an extract of root of Beta vulgaris and an extract of Polygonum cuspidatum. The present invention also relates to pharmaceutical formulations compositions comprising the phytological composition together with suitable pharmaceutically acceptable excipients.

Hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for topical use in the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain, as well as in the prevention or treatment of the symptoms of skin inflammation and of mucosal inflammation. The invention also relates to the use of these hyperbranched, and preferably hyperbranched and hydrogenated, dextrins to prevent or reduce or eliminate the irritant effect induced by ingredients contained in cosmetic or dermatological compositions.

Extracts of seaweed *Hygrophorus fusiforme* are used to reduce the amount of sebum produced by human skin and / or scalp, and / or to prevent and / or reduce and / or slow down and / or stop and / or alleviate the appearance of unsightly and / or uncomfortable and / or unpleasant manifestations of human skin and / or scalp due to sebum secretion, particularly in cosmetic or pharmaceutical compositions for topical use, especially dermatological compositions.

Topical composition comprising a combination comprising a) Phosphatidylglycerol b) Propanediol caprylate and at least one dermatologically or cosmetically acceptable excipient, for use as an adjuvant for the prevention and treatment of seborrhoeic dermatitis, and in the treatment and prevention of dandruff.

The present invention relates to a composition and method for solubilizing eggshell membrane at convenient rates. The present invention also relates to organoleptically acceptable products obtained therein, and to their oral or topical application to improve a disease or condition in a subject.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.